NTRK2 and neoplasm: Given that AZD7451 inhibits TrkB activation and tumor cell migration, as well as the observed crosstalk between EGFR and TrkB in other malignancies [35], we then combined this agent with erlotinib to determine the effect on multiple SCC and adenocarcinoma cell lines.